Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406107 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
A Phase 4 study of Branch Retinal Vein Occlusion, sponsored by Palmetto Retina Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT00406107 is a Phase 4 study of Branch Retinal Vein Occlusion that has completed, run by Palmetto Retina Center. The registered enrollment target is 20 participants, below the 2,065-participant average among 3 other Branch Retinal Vein Occlusion trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00406107, a Phase 4 study of Branch Retinal Vein Occlusion, has completed, sponsored by Palmetto Retina Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.
Conditions Studied
Interventions
- DRUG pegaptanib sodium (Macugen)
Study Locations (3)
California
- Jules Stein Eye Institute - Los Angeles
Maryland
- Cumberland Valley Retina Center - Hagerstown
South Carolina
- Palmetto Retina Center - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406107
The ClinicalTrials.gov registry entry for NCT00406107 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,065-participant average among 3 other Branch Retinal Vein Occlusion trials with a reported enrollment target (99% lower). The listed sponsor is Palmetto Retina Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Branch Retinal Vein Occlusion appearing as the primary indexed condition, and to 1 intervention - of which pegaptanib sodium (Macugen) is the first listed.
NCT00406107 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Maryland, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00406107 about?
NCT00406107 is a clinical study titled "Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion". The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VE...
What is the current status of trial NCT00406107?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-01. Estimated completion is 2008-04.
What conditions does trial NCT00406107 study?
This clinical trial studies the following conditions: Branch Retinal Vein Occlusion.
What interventions are being tested in trial NCT00406107?
The interventions under investigation include: pegaptanib sodium (Macugen) (DRUG).
Who is sponsoring clinical trial NCT00406107?
This trial is sponsored by Palmetto Retina Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406107 being conducted?
This trial has 3 study locations across California, Maryland, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Branch Retinal Vein Occlusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
ACTIVE NOT RECRUITING
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.